Recent developments in basic immunology have revealed the importance of glutathione (GSH) and cellular redox balance in the generation of an immune response. In the liver, it has been shown that exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters cellular GSH and reactive oxygen intermediate (ROI) production. We have tested the hypothesis that TCDD mediates the suppression of the cytotoxic T lymphocyte (CTL) response to alloantigen by increasing oxidative stress. Total cellular GSH, GSSG, and GSH-protein adducts were analyzed by HPLC. Changes in intracellular GSH and ROI were simultaneously measured in isolated hepatocytes and individual subpopulations of spleen cells (CD4 ؉ , CD8 ؉ , B220 ؉ , and Mac-1 ؉ ) following in vivo exposure to TCDD and antigenic challenge with P815 mastocytoma cells. Monochlorobimane was utilized to measure GSH levels, and two fluorescent probes were used to evaluate ROI levels: dichlorofluoroscein diacetate to monitor peroxides and dihydroethidine to assess superoxide anion. In hepatocytes, in vivo treatment with TCDD resulted in a transient, 2-fold increase in GSH, a 50% decrease in peroxide levels and a small (20 -40%) decrease in superoxide anion levels. Although alloantigen challenge resulted in increased GSH and peroxide in spleen cells, in vivo exposure to TCDD had no effect on splenic ROI levels, nor did it consistently alter GSH levels in any subpopulation of spleen cells examined. Moreover, in vivo treatment with the antioxidant Nacetyl cysteine failed to affect the immune suppression caused by TCDD. These results suggest to us that although TCDD perturbs cellular redox balance in the liver, it does not exacerbate or diminish the normal increased GSH and ROI which occur in the spleen in response to antigenic challenge.
The immune system is recognized as one of the most sensitive targets for the toxicity of 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), the prototype and most toxic member of a large group of structurally related chlorinated aromatic compounds that are widely dispersed in the environment. In laboratory animals, TCDD-induced immune dysfunction is characterized by suppression of acquired immunity, with both antibody and cell-mediated responses susceptible to suppression under different exposure paradigms (reviewed by Kerkvliet and Burleson, 1994) . In particular, in vivo exposure to TCDD leads to the dose-dependent suppression of T-cell functions, including cytokine production, proliferation, differentiation and T-cell-dependent B cell responses (Kerkvliet et al., 1990; Kerkvliet et al., 1996; Lundberg et al., 1992; Neumann et al., 1993; Prell et al., 1995; Tomar and Kerkvliet, 1991) . However, despite the rather profound effects of TCDD on T-cell functions in vivo, existing evidence indicates that T cells are not direct targets of TCDD. In vitro exposure of purified T cells to TCDD failed to alter their functional response to antigen challenge, including proliferation and cytokine production (DeKrey and Lang et al., 1994; Lundberg et al., 1992) . Moreover, unlike macrophages or B cells, exposure of T cells to TCDD failed to induce binding of the aryl hydrocarbon (Ah) receptor to a consensus dioxin response element (Lawrence et al., 1996) . Thus, in the absence of a direct effect of TCDD on T cells, indirect mechanisms have been sought to explain the observed defects in T-cell function following in vivo exposure to TCDD.
One emerging area of interest is the role of cellular redox balance in the generation of a successful immune response. For example, in addition to protecting cells from oxidative injury, the antioxidant glutathione (GSH) has been shown to modulate immune function. In a variety of experimental models, GSH has been found to play a role in the processing of protein antigens (Short et al., 1996) , T-cell activation Kavanagh et al., 1993; Otsuji et al., 1996; Peterson et al., 1998; Staal et al., 1994; Wilhelm et al., 1997) , lymphocyte proliferation (Fidelus et al., 1987; Gmunder et al., 1990a ; Smyth, 1991; Suthanthiran et al., 1990; Taylor et al., 1997; Walsh et al., 1995) , IL-2 receptor expression (Liang et al., 1992) , the expansion of CD8 ϩ T cells, and the generation of cytotoxic T lymphocyte (CTL) responses (Droge et al., 1986; Gmunder and Droge, 1991; Multhoff et al., 1995) . Similarly, the presence of reactive oxygen intermediates (ROI), or oxidative stress, has been demonstrated to influence a variety of immune functions. For example, exogenously added H 2 O 2 can modulate the activation of transcription factors NFB and AP-1, suggesting that a key step in their regulatory pathway is redox sensitive (Flescher et al., 1994; Mihm et al., 1995; Remick and Villarete, 1996; Sen and Packer, 1996; Suzuki et al., 1994) . ROI have also been implicated in both the enhancement and suppression of lymphocyte activation. For example, in vivo or in vitro addition of cellular antioxidants blocks lymphocyte activation, leading to the theory that small amounts of ROI are necessary for lymphocyte activation and differentiation (Fedyk and Phipps, 1994; Fidelus, 1988; Lahdenpohja et al., 1998; Sekkat et al., 1988) . In contrast, the addition of oxidants such as H 2 O 2 has been shown to suppress lymphocyte activation and proliferation (Duncan and Lawrence, 1990; Flescher et al., 1994) . Collectively, these findings support the emerging theory that a proper redox balance maintains optimum immune function, and that either antioxidant deficiency or oxidant overload can impair an immune response.
Exposure to TCDD has been shown to alter redox balance in hepatic and extrahepatic tissues of rats and mice. As reviewed by Stohs (1990) , much of this evidence includes enhanced in vivo and in vitro lipid peroxidation, increased hepatic and macrophage DNA damage, increased urinary excretion of malondialdehyde, and decreased GSH, nonprotein sulfhydryl and NADPH content of liver following exposure to TCDD. More recently, in vivo exposure to TCDD has been reported to increase the production of superoxide anion by murine peritoneal macrophages (Alsharif et al., 1994) , and in vitro studies of HIV infected cells provide suggestive evidence that TCDD may increase viral replication via a process involving increased oxidative stress (Gollipudi et al., 1996; Tsyrlov and Pokrovsky, 1993; Yao et al., 1995) . In contrast, a recent report by Shertzer et al. (1998) demonstrated an increase in hepatocyte GSH levels following in vitro treatment with TCDD. Given the important role of GSH and ROI in immune regulation and evidence that exposure to TCDD perturbs redox balance, we postulated that TCDD-induced immunotoxicity is driven by increased oxidative stress. We have studied the cellular and humoral immune response to allogeneic tumor cells (P815 mastocytoma cells) to test this hypothesis, and describe here an analysis of GSH and ROI levels in liver and spleen and an examination of the ability of excess antioxidants to compensate for or reverse TCDD-induced suppression the of immune response to P815 challenge.
MATERIALS AND METHODS
Reagents. Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT). Unless indicated otherwise, all other reagents and cell culture supplies were purchased from Sigma Chemical Co. (St. Louis, MO).
Animals.
Male C57Bl/6J mice and female DBA/2J mice (The Jackson Laboratory, Bar Harbor, ME) 6 -8 weeks of age were maintained in front of a laminar flow unit and given rodent chow and tap water ad libitum. DBA/2J mice were housed six per cage and were used for weekly in vivo propagation of the P815 mastocytoma cells. Male C57Bl/6J mice were housed singly, whereas female DBA/2J mice were housed six per cage.
In vivo TCDD treatment and antigen challenge. TCDD (Ն 99% purity, Cambridge Isotopes, Inc., Woburn, MA) was dissolved in anisole and diluted in peanut oil. Male C57Bl/6J mice were given a known immunosuppressive dose of TCDD by gavage (15 g/kg body weight) (DeKrey and . Control mice received the peanut oil-anisole vehicle. One day following exposure to TCDD, mice were challenged by intraperitoneal injection with 1ϫ10 7 viable P815 mastocytoma cells. Animals were killed by CO 2 overdose at various times after antigen treatment. Blood was collect by heart puncture into syringes containing anticoagulant (sodium heparin). Plasma was processed and stored at -80°C. Spleens were removed and processed into a single-cell suspension. Isolated hepatocytes were obtained by the method of Fariss et al. (1985) with the modification that the isolated cells were washed and resuspended in PBS containing 4% FBS and 0.02% sodium azide prior to counting and staining.
Cell culture. Hepa 1c1c7 cells (from James Whitlock, Stanford University) were maintained in MEM␣ containing 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin. For in vitro experiments, TCDD was dissolved in DMSO and used at a final concentration of 1 or 10 nM (in 0.01% DMSO). Control cultures were adjusted to 0.01% DMSO in the media.
Flow cytometric analysis. Spleen cell subsets were defined using anti-CD4, anti-CD8, anti-Mac-1 (CD11b), or anti-CD19 monoclonal antibodies. For one experiment, an anti-B220 antibody was used in lieu of anti-CD19 to detect splenic B lymphocytes. Cells were incubated with previously determined optimal concentrations of fluorochrome-conjugated antibodies. Appropriately labeled, isotype-matched antibodies were used as controls for nonspecific fluorescence. Because hepatocytes were not cell-surface stained with antibodies, unstained cells were used to control for cellular autofluorescence. Data were collected from 25,000 to 50,000 cells by listmode acquisition using either an EPICS V or an XL-2 flow cytometer (Coulter Electronics, Hialeah, FL). Dead cells, clumps, and debris were excluded from analyses using a combination of forward angle and 90°light scatter and propidium iodide exclusion. Data were analyzed using WinList software (Verity Software, Topsham, ME).
GSH Measurement
HPLC method. GSH, GSSG, and mixed disulfide levels in spleen cells were determined by HPLC according to the previously described methods (Martin and White, 1991) . Briefly, spleen cells (4ϫ10 6 ) were deproteinated by centrifugation through oil into a solution containing 10% perchloric acid. GSH and GSSG released into the supernatant were derivatized with dansyl chloride and separated using a linear gradient (0.04 -0.8 M sodium acetate, pH 4.5 in 80% methanol) on an aminopropyl silica column. Derivatized GSH and GSSG were detected with an fluorescence detection system and compared to known standards. Included with each sample was a ␥-glu-glu internal standard. GSS-protein mixed disulfides were determined by the method of Livesey and Reed (1984) . Briefly, the acid pellet was reduced with dithiothreitol and the released GSH was then quantified by HPLC, as described above.
Flow cytometric method I, monochlorobimane. Monochlorobimane (MCB, from Molecular Probes, Eugene, OR) is a membrane-permeable fluorochrome that conjugates specifically to reduced GSH, and the intensity of MCB staining is directly proportional to the intracellular GSH concentration (Hedley and Chow, 1994; Rice et al., 1986) . MCB staining was performed as described by Roederer et al. (1991) . Briefly, freshly isolated cells were resuspended in RPMI without carbonate, supplemented with 10 mM HEPES, 4% FBS, and 0.02% sodium azide (hRPMI). Cells were adjusted to 2ϫ10 6 /ml and stained with 1 M MCB for 20 min at 22°C. The staining reaction was quenched with an excess (10-fold) volume of cold hRPMI containing 2.5 mM probenecid, and the cells were either analyzed immediately or labeled with fluorescently conjugated cell-surface markers prior to analysis by flow cytometry. Cells that were not stained with MCB were used as controls for autofluoresence.
Flow cytometric method II, anti-GS-NEM monoclonal antibody.
Isolated cells were resuspended in PBS (4ϫ10 6 /ml), fixed in 2% formaldehyde, then permeabilized at -70°C in methanol containing 10 mM N-ethylmaleimide (NEM), which binds with reduced intracellular GSH, forming GS-NEM conjugates. Fixed and permeabilized cells were washed in PBS containing 1 mM glycine (pH 7.4) and resuspended in PBS containing 5% FBS and 1 mg/ml rat IgG to block nonspecific binding. Mouse anti-GS-NEM (gift from D. Lawrence, NYS Dept. of Health) was added to each sample at a final concentration of 1:100, and cells were maintained on ice for 30 min. Excess antibody was removed by washing with PBS, supplemented with 5% FBS prior to the addition of FITC-conjugated goat anti-mouse IgG (Fab 2 fragment, diluted 1:500). The cells were incubated with secondary antibody for 30 min, washed and then either analyzed immediately by flow cytometry or labeled with fluorescently-conjugated cell-surface markers prior to analysis. Samples that were incubated with secondary antibody alone were used as controls for nonspecific fluorescence.
ROI measurements.
Hydroperoxide formation was monitored using the oxidant-sensitive fluorescent probe 6-carboxy-2Ј7Ј-dichlorofluorescein diacetate, di(acetoxymethyl ester) (DCFH-DA, Molecular Probes). Once taken up into cells, the nonfluorescent parent compound is oxidized by cellular peroxides, forming the fluorescent product 2Ј7Ј-dichlorofluorescein (DCF) (Bass et al., 1983; Hockenberry et al., 1993; Kohno et al., 1996; Zamzami et al., 1995) . In several in vitro experiments, an additional peroxide-sensitive fluorescent probe, dihydrorhodamine 123 (DHR, Molecular Probes), was used in addition to DCFH-DA. Cellular superoxide anion levels were monitored using the fluorescent indicator dihydroethidine (HE, Molecular Probes), which reacts with oxygen radicals such as superoxide anion to form ethidium (Perticarari et al., 1991) .
ROI levels were measured in individual populations of freshly isolated cells that had been resuspended in PBS containing 4% FBS and 0.02% sodium azide (PAF), adjusted to a concentration of 2.5ϫ10 6 /ml, and incubated for 15 min at 37°C with a particular probe. The final concentration of each probe was as follows: DCFH-DA, 5 M; DHR, 1ϫ10 5 nM; and HE, 100 ng/ml. Excess stain was removed by washing with PAF and the cells were either analyzed directly or labeled with fluorescently conjugated cell-surface markers prior to analysis.
In vivo administration of N-acetyl-L-cysteine. N-acetyl-L-cysteine (NAC) (10 mg/ml) was administered in the drinking water. This dose was selected based upon other in vivo studies (Yim et al., 1994) , and the efficacy was verified in this experiment by the examination of Fas (CD95) expression on splenic lymphocytes (Chiba et al., 1996; Deas et al., 1996; Delneste et al., 1996) . Furthermore, water consumption was measured daily and water bottles were exchanged every other day to decrease the effects of NAC oxidation and concentration fluctuations due to evaporation. The addition of NAC to drinking water did not influence the amount of water consumed by the mice, nor did it affect animal body weight.
CTL assay. The cytolytic activity of spleen cells to P815 tumor cells was measured by 4-h 51 Cr release assay (De Krey and Kerkvliet, 1995) . E:T ratios from 200:1 to 12.5:1 were tested in triplicate. The percent cytotoxicity for each E:T ratio was calculated using the following equation:
% cytotoxicity ϭ ͓͑experimental release-naive release͒ր maximum release-spontaneous release͔͒ ϫ 100 Cytotoxic alloantibody assay. Plasma P815-specific antibody titers were measured using a complement-dependent 51 Cr release assay . The antibody titer was defined as the highest dilution of plasma at which a minimum of 20% specific cytotoxicity was measured. The titer was transformed to log 2 dilution for statistical analysis.
Data analysis. All data were analyzed using Statview (version. 4.01, Abacus Concepts, Berkeley, CA) statistical software for Macintosh. An analysis of variance (ANOVA) was used, followed by post hoc tests (Fisher PLSD) to compare independent variables over time and between each treatment group. Except as noted in the text, values of p Յ 0.05 were considered statistically significant.
RESULTS

In vivo Exposure to an Immunotoxic Dose of TCDD Does Not Change Splenocyte GSH or ROI Levels
Although the effects of TCDD on oxidative stress have been examined in other cells and tissues, there is little information regarding its impact on changes in cellular redox balance during the course of an immune response. Moreover, most of the previous in vivo studies were performed using a 50 -100 g/kg dose of TCDD, a dose that far exceeds an immunotoxic dose (Kerkvliet and Burleson, 1994) . We therefore examined whether exposure to a lower but known immunotoxic dose of TCDD alters spleen cell GSH and ROI levels. As shown in Figure 1 , antigenic (P815) challenge alone led to increased levels of splenic GSH, as measured by a significant increase in MCB fluorescence intensity over time. When compared to naive animals, the most notable alteration was a 1.5-fold increase in GSH levels in Mac-1 ϩ spleen cells (i.e., a change in mean channel fluorescence from 98 to 160). P815 challenge also induced an approximately 10% increase in GSH in CD4 ϩ , CD8 ϩ , and CD19 ϩ spleen cells. Similar results were obtained using an anti-GS-NEM monoclonal antibody instead of MCB (data not shown). However, exposure to TCDD did not significantly alter the magnitude or direction of changes in GSH levels in the spleen. Aside from a small (10 -15%) increase in MCB staining in Mac-1 ϩ cells (Figure 1, panel A) , spleen cell subpopulations from mice exposed to TCDD and challenged with antigen exhibited the same profile of increased GSH as spleen cells from vehicle control mice. Moreover, the change in macrophage GSH content caused by TCDD was observed in only three out of five separate time-course experiments, and a study of three different murine macrophage cell lines failed to demonstrate an in vitro effect of TCDD on macrophage GSH levels (data not shown).
An examination of splenic peroxide levels using DCFH-DA revealed that P815 challenge alone also caused a significant increase in peroxide levels in the spleen, leading to a 1.5-to 1.8-fold increase in T cells and macrophages and a 1.3-fold increase in splenic B cells 5 days after alloantigen challenge (Figure 1, panel B) . However, with the exception of a small (10 -15%) increase in macrophage DCF staining, exposure to TCDD did not alter the magnitude of the antigen-induced increase in splenic peroxides. Individual subpopulations of spleen cells were also stained with HE to examine superoxide anion; however the levels of fluorescence detected were extremely low and no differences were observed in any treatment group (data not shown).
FIG. 1.
P815 mastocytoma challenge causes an increase in spleen cell GSH and peroxide. Male C57Bl/6 mice were given a single oral dose of either TCDD (15 g/kg) or peanut oil vehicle 1 day prior to the intraperitoneal injection of 1ϫ10 7 P815 tumor cells. Single-cell suspensions of spleen cells were prepared for 5 consecutive days and intracellular levels of GSH and ROI were measured using the indicated fluorescent probes, as described in Materials and Methods. Spleen cell subsets were differentiated using fluorochrome-conjugated anti-CD4, anti-CD8, anti-CD19, or anti-Mac-1 (CD11b) monoclonal antibodies. GSH and peroxide levels were measured in spleen cells from vehicle-(open circles) and TCDD-(closed circles) treated mice (five mice per treatment group per day). As a control, splenic GSH and hydroperoxide levels were also measured in cells from one naive mouse (triangle) daily, and the results are presented as the average from all 5 days. Data points represent the average mean channel fluorescence (Ϯ SEM). The data represent information acquired from one consecutive time-course experiment; the entire time course was repeated two times with similar results. *Significant difference between vehicle and TCDD groups (p Յ 0.05).
Exposure to TCDD does not alter the ratio of splenic GSH to GSSG
Another characteristic of oxidative stress is an alteration in the ratio of reduced and oxidized GSH (Reed, 1990) . Therefore, we measured GSH, GSSG, and glutathionemixed disulfide levels (protein adducts) in spleen cells following exposure to TCDD (Figure 2 ). When compared with naive animals, alloantigen challenge resulted in an increased level of GSH on day 5, and exposure to TCDD neither increased nor decreased this level. Thus, these results parallel the data obtained using flow cytometric methods in which we observed an antigen-induced increase in GSH. Moreover, compared with naive animals, there was a corresponding decrease in splenic GSSG in both the vehicleand TCDD-treated, P815-challenged groups ( Figure 2B ). It should be noted that there was no statistically significant difference between the vehicle-and TCDD-treated groups on any day. With regard to the level of protein-mixed disulfides ( Figure 2C ), there were no differences in the level detected in spleen cells from naive, vehicle-and TCDDtreated mice on any day examined.
In Vivo and in Vitro Treatment with TCDD Alters Hepatocyte Redox Balance
Given the absence of an effect of TCDD on splenic GSH or peroxide levels, we examined whether this dose of TCDD altered hepatocyte redox balance. In the same time-course experiment in which splenic GSH and ROI levels were measured, two animals per group per day were selected at random and the in vivo effects of TCDD on liver GSH and ROI levels were determined. As shown in Figure 3 , a single 15-g/kg dose of TCDD resulted in a transient 2-fold increase in hepatocyte GSH, a 50% reduction in hepatocyte peroxide levels, and a 20 -40% decrease in superoxide anion levels. To corroborate these findings, we also used a cultured hepatocyte cell line. Following a 24-h exposure to TCDD, hepa1c1c7 cells exhibited a pattern of changes similar to that observed in hepatocytes following in vivo exposure to TCDD. Specifically, exposure of hepa1c1c7 cells to TCDD caused a dose-responsive increase in reduced GSH and decreased superoxide anion and hydroperoxide levels (Figure 4) .
Provision of Excess Antioxidant Does Not Compensate for or Correct TCDD-Induced Suppression of the CTL and Alloantibody Responses to P815
Although no significant change in splenic GSH or ROI could be detected following exposure to TCDD, the changes observed in hepatocytes demonstrated that exposure to this dose of TCDD caused some changes redox balance in the liver. To further examine whether exposure to TCDD mediates immune suppression via an increase in oxidative stress, we also determined whether the provision of NAC would compensate for or reverse TCDD-induced suppression of the CTL and antibody response to P815 challenge. The administration of exogenous thiols such as NAC has been shown to restore many immune responses that are perturbed by changes in redox balance (Breithaupt et al., 1996; Droge et al., 1991; Herzenberg et al., 1997; Omara et al., 1997; Otsuji et al., 1996; Yim et al., 1994) . NAC (10
FIG. 2.
In vivo exposure to TCDD does not alter splenic GSH, GSSG or GSS-protein levels. HPLC analysis of GSH, GSSG, and GSS-protein in spleen cells (4ϫ10 6 ) was conducted on days 1 through 5 following in vivo alloantigen (P815) challenge and exposure to TCDD (15 g/kg). Data points represent the average peak area (Ϯ SEM) from five vehicle-(open circles) and TCDD-(closed circles) treated mice per day. As a control, splenic GSH, GSSG and glutathione-mixed disulfide levels were also measured in spleen cells from one naive mouse (triangle) daily, and the results are presented as the average level (Ϯ SEM) from all 5 days. mg/ml) was administered in the drinking water at the time of treatment with TCDD, and mice were maintained on this water for the duration of the experiment. As shown in Figure  5 , NAC treatment was unable to reverse the suppression of CTL activity and cytotoxic alloantibody production caused by TCDD. In other model systems, NAC leads to a decrease in activation-induced expression of Fas on lymphocytes (Chiba et al., 1996; Deas et al., 1996; Delneste et al., 1996) . As a positive control for the efficacy of NAC in this experiment, we exploited this phenomenon. As determined by flow cytometry, the administration of NAC in drinking water reduced activation-induced Fas expression on splenic CD4 ϩ (10 -30% decrease), CD8 ϩ (50 -60%), and B220 ϩ (45-55%) lymphocytes in both the vehicle control and TCDD-treated groups (data not shown).
DISCUSSION
The purpose of this study was to test the hypothesis that the immune suppression caused by exposure to TCDD is mediated, at least in part, by increased oxidative stress. This hypothesis was based upon two observations: first, it has been shown that exposure to TCDD alters cellular GSH and ROI levels in the liver, and second, recent developments in basic immunology have revealed the importance of GSH and ROI in the development of an immune response.
FIG. 3.
Time course of the in vivo effects of exposure to TCDD on liver GSH and ROI levels. Hepatocytes were isolated daily from two randomly selected animals during the experiment described in Figure 1 . Single cell suspensions of isolated hepatocytes were prepared for 5 consecutive days and intracellular levels of GSH and ROI were measured using the indicated fluorescent probes, as described in Materials and Methods. The data in the top portion of each panel represent the average mean channel fluorescence (Ϯ SEM) of reduced GSH (MCB staining, panel A), peroxide (DCF staining, panel B) or superoxide anion (HE staining, panel C) over the 5-day time course following in vivo exposure to either vehicle (open bars) or TCDD (black bars). There were two mice per treatment group per day. The bottom portion of each panel shows one representative histogram (day 2), comparing hepatocytes from vehicle-(gray line) and TCDD-treated (black line) mice. The autofluorescence from unstained hepatocytes is indicated with a dashed line. *Indicates a difference from control hepatocytes (p Յ 0.08).
Whereas several in vivo studies have demonstrated a correlation between decreased GSH and immune suppression (Herzenberg et al., 1997; Peterson et al., 1998; Taylor et al., 1997) , much of our understanding of the role of GSH in the initiation and maintenance of an immune response has been deduced from studies in which the effects of GSH depletion were examined in vitro (Droge et al., 1994; Kavanagh et al., 1993; Potter et al., 1997; Short et al., 1996; Staal et al., 1994; Suthanthiran et al., 1990) . Similarly, our awareness of the necessity for a small increase in oxidants has arisen from a multitude of in vitro studies examining either the consequences of the addition of exogenous oxidants or the effect of excess antioxidants (Fidelus et al., 1988; Ginn-Pease and Whisler, 1996; Goldstone et al., 1995; Lahdenpohja et al., 1998; Remick and Villarete, 1996; Williams and Henkart, 1996) . Collectively, these studies have given rise to the current model in which early events in T-cell activation require changes in cellular redox balance, including an increase in cellular thiols such as GSH, and a small burst in ROI (Droge et al., 1994; Nakamura et al., 1997; Sen and Packer, 1996) .
To the best of our knowledge, our results document for the first time the in vivo progression of antigen-induced changes in GSH and peroxide in splenic lymphocytes and macrophages. Furthermore, when put into the context of the events that take place in the spleen in response to P815 mastocytoma challenge, our findings correlate very well with the in vitro observations from many laboratories. For example, an in vitro examination of the relationship between lymphocyte GSH levels and cytokine production indicated that increased lymphocyte GSH occurs prior to IL-2 production (Gmunder et al., 1990b; Gmunder and Droge, FIG. 5 . In vivo treatment with NAC fails to reverse TCDD-induced suppression of either the CTL and antibody responses to P815 tumor challenge. Male C57Bl6/J mice (nϭ12) were given a single oral dose of either TCDD (15 g/kg) or peanut oil vehicle 1 day prior to the intraperitoneal injection of P815 tumor cells. During the entire experiment, half the mice in each group were administered NAC (10 mg/ml, in their drinking water, as described in Materials and Methods). A. The cytolytic activity of spleen cells to P815 tumor cells was measured by 4-h 51 Cr release assay on day 10. B. Plasma levels of P815-specific antibodies were determined using a complement-dependent 51 Cr release assay. As described in the Materials and Methods, the antibody titer was defined as the highest dilution of plasma at which a minimum of 20% specific cytotoxicity was measured. Data represent the mean ϮSEM (nϭ6). *Significant difference from control animals (p Յ 0.05).
FIG. 4.
In vitro exposure to TCDD causes dose-dependent changes in GSH and ROI levels in Hepa1c1c7 cells. Hepa1c1c7 cells were treated with 1 nM TCDD, 10 nM TCDD, or 0.01% DMSO (control) for 24 h. The relative amount of reduced GSH (panel A) and ROI (panels B-D) was measured by flow cytometry using the indicated intracellular probes, as described in Materials and Methods. Data represent the average mean channel fluorescence of cells obtained from three to four separate flasks of each treatment group (Ϯ SEM). Results similar to those acquired using the anti-GS-NEM MAb were obtained using MCB (data not shown). *Significantly different from the control (p Յ 0.05).
1991). In our study, concomitant measurement of IL-2 and GSH levels in the spleen following challenge with P815 cells revealed that increased splenic GSH preceded the onset of IL-2 production (our unpublished observations). Likewise, our finding that splenic ROI and GSH levels increased prior to the expansion of effector cells is consistent with reported in vitro observations that both GSH and small amounts of ROI are necessary to drive T-cell differentiation. Finally, when splenic GSH levels were examined 10 days after P815 challenge, there was no difference between alloantigen-sensitized and naive mice, suggesting that increased GSH is transient and occurs during cellular activation and proliferation but not during the effector phase (unpublished observations). Although the precise course of events may differ following in vivo challenge with a different antigen, the fact that our data are congruous with in vitro studies suggests that these changes in cellular oxidants and antioxidants may indeed be universal to adaptive immune responses.
Interestingly, our in vivo and in vitro hepatocyte data indicated that TCDD increased rather than decreased GSH levels. These findings are consistent with a very recent report by Shertzer et al. (1998) in which they also found that treatment of hepa1c1c7 cells with TCDD resulted in increased GSH. Mechanistically speaking, these data are somewhat enigmatic in that it is difficult to explain how exposure to TCDD leads to an augmentation in cellular GSH levels. One explanation is that the increased GSH reflects a prior oxidative insult to which the cells are responding. To address whether the observed increase in GSH (and decrease in ROI) levels were due to a recovery from oxidative stress, we examined GSH and ROI levels in hepa1c1c7 cells at 2, 6, 12, and 24 h following exposure to 1 nM and 10 nM TCDD. Using fluorescent probes, at no time was a decrease in GSH or an increase in ROI levels observed (unpublished data). Thus, it appears that the effects of TCDD on cellular redox balance may be biphasic, with higher levels of exposure leading to classic oxidative stress and lower level exposure leading to a very slight inverse effect. The physiological consequences of small increases in hepatocyte GSH and decreases in hepatocyte ROI remain to be determined.
With regard to the immunosuppression induced by TCDD, our data indicate that increased oxidative stress is not the underlying cause. Specifically, the inability of in vivo NAC treatment to reverse TCDD-induced suppression of the CTL and antibody response to P815, combined with the observation that TCDD does not perturb antigen-induced alterations in splenic GSH or peroxide, provide strong evidence that increased oxidative stress does not play a major role in TCDD immunotoxicity. At first glance this finding was surprising, given that there are several reports that document increased oxidative stress following exposure to TCDD (Alsharif et al., 1994; Stohs et al., 1990) . However, most of these studies were conducted using a much higher dose of TCDD (50 -100 g/kg body weight). Furthermore, although Alsharif et al. (1994) reported that in vivo exposure to Ն 25 g/kg TCDD increased superoxide anion production in peritoneal macrophages, they also reported that this effect was not reproducible in either cultured peritoneal cells or a macrophage cell line following in vitro exposure to TCDD. Thus, it seems likely that the ability of TCDD to cause GSH depletion or increased ROI production is dependent on both the dose of TCDD and the model system.
Our findings relating to the lack of effect of TCDD on cellular redox balance in the spleen are consistent with other aspects of this immunotoxicity model. First, the induction of proinflammatory cytokines such as IL-1 and TNF has been shown to increase the production of ROI (Cavaillon, 1994; Laskin and Pendino, 1995) . In other model systems, TCDD treatment leads to enhanced levels of IL-1 and TNF, suggesting that this is a mechanism by which exposure to TCDD could cause oxidative stress (Fan et al., 1997; Moos et al., 1997; Sutter et al., 1991; Yin et al., 1994) . However, in the context of the response to P815 cells, exposure to TCDD did not increase the production of IL-1 or TNF Lawrence and Kerkvliet, 1998) . In fact, treatment with TCDD suppressed the levels of TNF produced by spleen cells in response to P815 challenge . Second, both an increase in ROI and decreased GSH have been correlated with the induction of apoptosis (Beaver and Waring, 1995; Chiba et al., 1996; Kohno et al., 1996; Williams and Henkart, 1996) . However, an examination of the time course of Fas (CD95) expression and apoptosis in splenic T-cells following exposure to TCDD and challenge with P815 cells failed to demonstrate increased apoptosis or alterations in Fas expression on T-cells from TCDD-treated mice (Dearstyne and Kerkvliet, unpublished observations). Although circumstantial, these two related observations are consistent with the finding that exposure to TCDD does not cause increased ROI or GSH depletion.
In conclusion, we have found that primary antigenic challenge with allogeneic P815 mastocytoma cells increased GSH and ROI levels in splenic lymphocytes and macrophages from C57Bl/6 mice, and these changes preceded CTL proliferation and differentiation. We have also determined that in vivo exposure to a low but immunotoxic dose of TCDD caused modest changes in GSH and ROI levels in hepatocytes, but the redox status of spleen cell subsets was not significantly altered. Combined with the inability of NAC to abrogate TCDD-induced suppression of the response to P815 challenge, we conclude that, within the context of this model, increased oxidative stress is unlikely to underlie TCDD immunotoxicity. expertise on measuring intracellular GSH using monochlorobimane, Dr. David Lawrence (NYS Dept. of Health) for the gift of anti-GS-NEM monoclonal antibody, and Dr. Catherine Gardiner (Univ. Northern Colorado) for assistance with the dansyl chloride method for detecting GSH. For their excellent technical support and assistance with several experiments, the authors also thank Marda Brown, Julie Oughton, and Linda Steppan. This work was supported by grants ES05667 (BPL) and ES00210 and ES00040 (NIK and DJR) from the National Institute of Environmental Health Sciences, National Institutes of Health.
